$ALKS

Alkermes (NASDAQ: ALKS) exec lines up $423K stock sale

Alkermes (ALKS) officer Craig C. Hopkinson filed a Rule 144 notice for potential sales of 9,000 ordinary shares, valued at $422,874.27. The shares include those from an employee stock option exercise, performance share award vesting, and restricted stock unit vesting. Alkermes had 167,763,272 ordinary shares outstanding as of 09/01/2026.

Original reporting
Published Sep 1, 2026, 8:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 1, 2026, 11:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$ALKS
Neutral
medium confidence
Mentioned
$ALKS
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ALKSNeutralLow
01

Why it matters

The disclosed sale adds a modest amount of shares to the market, likely causing negligible price movement.

02

Market read

Routine insider sale with limited trading impact.

03

What to watch

Potential tax planning or liquidity needs unrelated to company performance.

Relevance 4/10Novelty 4/10Timing: 09/01/2026 filing date

Background

Rule 144 filings allow insiders to sell restricted shares after meeting holding periods, often signaling upcoming supply.

Company-level read

Ticker impact

$ALKSNeutralMedium confidence
Context

Alkermes officer filed a Rule 144 notice to sell 9,000 shares worth about $423K, indicating potential new supply to the market.

Expected impact

Minor short-term dip, limited to a few basis points.

Evidence & confidence

The sale size is small relative to float and typical for routine insider transactions.

Market effects

Minimal impact on the biotech sector; similar insider sales are common.

No significant regional effect.

Limited to Alkermes investors.

Counterpoint

The sale may be a signal of insider confidence if the shares are being sold at a premium.

Key entities

  • Craig C. Hopkinson

    Alkermes officer filing the Rule 144 notice.

Related articles

$ALKSMedAI 8/10

Phase 2 Data on Investigational Narcolepsy Drug Published

Alkermes' investigational narcolepsy drug alixorexton showed statistically significant improvements in wakefulness and cataplexy in a phase 2 study. The treatment was well-tolerated and improved patient-reported outcomes. The company has initiated a phase 3 program based on these results, according to the company.

$ALKSMedAI 9/10

Did Positive Vibrance-1 Data and Brilliance Phase 3 Launch Just Shift Alkermes' (ALKS) Investment Narrative?

Alkermes (ALKS) reported positive Phase 2 data for alixorexton in narcolepsy, leading to a global Phase 3 trial launch. The data, published in The Lancet Neurology, showed significant improvements in wakefulness and safety. The company aims for $2.3B revenue by 2029, with analysts projecting up to $2.8B. Success hinges on Phase 3 trial outcomes.

$ALKSMedAI 8/10

Alkermes plc: The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

Alkermes (ALKS) announced positive phase 2 study results for alixorexton in adults with narcolepsy type 1, published in The Lancet Neurology. The study showed statistically significant improvements in wakefulness and cataplexy, with all doses well-tolerated. Alkermes has initiated phase 3 trials for alixorexton in narcolepsy types 1 and 2.